BioSimilar

Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® in IV and SC Formulations

AVTOZMA® will be available as both intravenous (IV) and subcutaneous (SC) formulations with the same formulations and dosages as the reference p...

 January 31, 2025 | News

Taiwan’s Taikang Biotech Joins Forces with Mitsubishi Gas Chemical and Taiwan Sugar Alliance to Propel SPD8 Biosimilar Globally

Taikang Biotech (6589), Mitsubishi Gas Chemical Co., Ltd. (MGC), and the Taiwan Sugar Association (4168) have entered into a strategic tripartite agreement...

 December 26, 2024 | News

CHMP Endorses Celltrion’s Biosimilars Eydenzelt Stoboclo Osenvelt and Avtozma for Expanded Access to Biologic Treatments

The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinions for Celltrion’s three biosimilar candidates – Eydenz...

 December 16, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

 July 17, 2024 | News

Biocon Biologics Teams Up with Sandoz Australia for Biosimilar Trastuzumab and Bevacizumab

Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilita...

 February 09, 2024 | News

Mabxience and Abbott Forge Strategic Deal to Expand Biosimilars Access in Emerging Markets

Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia and Middle East and Africa mAbxience Holdi...

 September 21, 2023 | News

Celltrion Celebrates a Decade of Biosimilar Innovation in Europe

Marking 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indication...

 September 11, 2023 | News

Mabwell's Biosimilar Denosumab solution approved by NMPA for osteoporosis treatment

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (...

 April 04, 2023 | News

Altos Biologics Enrolls Patients in Global Phase 3 Trial for Eylea® Biosimilar in Neovascular Age-related Macular Degeneration.

  Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out disc...

 February 23, 2023 | News

Amjevita™ (Adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States

Amgen (NASDAQ:AMGN)  announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...

 February 01, 2023 | News

BGI Group Continues To Lead In Life Sciences 22 Years After The Human Genome Project

BGI was formed to be a part of the HGP, contributing to the sequencing of genes and working alongside scientists from six countries. Twenty-two years ago t...

 June 28, 2022 | News

GenScript establishes Korean legal entity and accelerates sales activities

GenScript Biotech Korea Ltd. has built a nest at IKP (Invest Korea Plaza) in Heolleung-ro, Seocho-gu, Seoul. The main purpose of the establishment of ...

 October 05, 2021 | News

Intas, First Indian company to launch a biosimilar product in the EU

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreeme...

 July 22, 2021 | News

Merck Receives Patent for Improved CRISPR Genome-Editing Method in Japan

Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research Helps modify difficult-to-access regions ...

 June 23, 2021 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close